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Histone acetylation constitutes an epigenetic mark
for transcriptional regulation. Here we developed
a fluorescent probe to visualize acetylation of histone
H4 Lys12 (H4K12) in living cells using fluorescence
resonance energy transfer (FRET) and the binding
of the BRD2 bromodomain to acetylated H4K12.
Using this probe designated as Histac-K12, we
demonstrated that histone H4K12 acetylation is re-
tained in mitosis and that some histone deacetylase
(HDAC) inhibitors continue to inhibit cellular HDAC
activity even after their removal from the culture. In
addition, a small molecule that interferes with ability
of the bromodomain to bind to acetylated H4K12
could be assessed using Histac-K12 in cells. Thus,
Histac-K12 will serve as a powerful tool not only to
understand the dynamics of H4K12-specific acetyla-
tion but also to characterize small molecules that
modulate the acetylation or interaction status of
histones.
INTRODUCTION
Covalent modifications of core histones play an important role in
modulating chromatin structure and function. In particular,
histone acetylation is a well-characterized modification that is
regulated by histone acetyltransferases (HATs) and histone de-
acetylases (HDACs) and is evolutionarily conserved from yeast
to humans (Khochbin et al., 2001; Yang and Seto, 2007). Histone
acetylation occurs on lysine residues in the N-terminal tails of
core histones and leads to transcriptional activation by recruiting
general transcriptional factors and transcriptional coactivators to
the chromatinized promoter region. Moreover, recent studies
suggest that site-specific histone acetylation plays a distinct
role in diverse cellular functions via generating histone codesChemistry & Biology 18,(Strahl and Allis, 2000; Turner, 2002). For example, acetylation
of histone H4K16 and H3K56 is critical for the cellular DNA
damage response and double-stranded break (DSB) repair.
Studies have shown that deregulated H4K12 acetylation is
a biomarker of age-related impairment in hippocampus-depen-
dent memory formation in mice (Sharma et al., 2010; Peleg
et al., 2010). The histone code hypothesis, initially proposed by
Jenuwein and Allis (2001), suggests that various combinations
of histone modifications constitute an epigenetic marking
system that regulates specific and distinct functional outputs
of eukaryotic genomes. These epigenetic marks are ‘‘written’’
by histone-modifying enzymes, ‘‘read’’ by proteins that specifi-
cally bind to single or combined histone modification site(s),
and ‘‘erased’’ by histone demodification enzymes (Chi et al.,
2010). Therefore, when, where, and how site-specific histone
acetylation is induced or maintained in living cells should be
tightly regulated. However, to date, there has not been a method
that can be used to analyze and quantify site-specific histone
acetylation levels in living cells at a high spatial and temporal
resolution. Recently, we successfully developed the first fluores-
cent probe, named Histac, that visualizes acetylated K5/K8 of
histone H4 in living cells. This technique was based on the idea
that conformational changes upon acetylation can alter FRET
generated in the fusion protein of histone H4 and testis-specific
bromodomain-containing protein (BRDT), which was further
tandemly fused with donor and acceptor fluorescent proteins
(Sasaki et al., 2009). UsingHistac, we demonstrated the dynamic
fluctuations in the H4K5/K8 acetylation levels during mitosis.
The bromodomain consists of approximately 110 amino acids
and specifically recognizes acetylated lysine residues.
Conserved bromodomains are found in many chromatin-associ-
ated proteins, including HATs such as PCAF and TAF1, and the
BET family of nuclear proteins, including BRD2, BRD3, BRD4,
andBRDT (Zeng andZhou, 2002). Because a variety of transcrip-
tional regulators and chromatin-remodeling proteins contain
bromodomains, they should recognize diverse acetylated
histonemotifs (Agalioti et al., 2002; Hassan et al., 2002; Ladurner
et al., 2003;Matangkasombut andBuratowski, 2003). Indeed, the
BRD2 bromodomain specifically recognizes the acetylation of495–507, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 495
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Figure 1. A Novel Fluorescent Probe for
Visualizing Histone H4K12 Acetylation in
Living Cells
(A) Schematic representation of the domain
structure of Histac-K12.
(B) Venus and Hoechst 33342-stained images are
shown in green and red, respectively. The fluo-
rescent images were collected using a confocal
microscope system.
See Figure S1.
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Real-Time Imaging of Histone H4K12 Acetylationhistone H4 Lys12 (H4K12) (Kanno et al., 2004; Umehara et al.,
2010a), whereas BD1 of BRDT binds to histone H4 that is diace-
tylated at K5 and K8 (Morinie`re et al., 2009). Therefore, it is
possible that similar Histac-like FRET imaging probes using
different bromodomains can be used to visualize different acety-
lation sites. In this study, we developed a novel probe that specif-
ically recognizes H4K12 acetylation in living cells using the BRD2
bromodomain region. Using this probe, we performed a time-
course analysis to demonstrate that the H4K12 acetylation level
was retained during mitosis, in contrast to the decrease in
H4K5/K8 acetylation in mitotic chromosomes. In addition, we
analyzed the kinetics of histone acetylation upon treatment with
various HDAC inhibitors. Furthermore, we showed that the probe
was capable of detecting the activity of a small molecule that
binds to the bromodomain cavity, which is required to recognize
K12-acetylated histone H4 in living cells.
RESULTS
Design of a Novel Fluorescent Indicator to Visualize
Site-Specific Acetylation
To develop a novel fluorescent probe to visualize histone H4K12
acetylation, we constructed an expression vector encoding five-
part tandem fusion proteins containing the bromodomain region
of BRD2, a flexible linker consisting of repeated GGGGS
sequences, the substrate histone H4, and two fluorophores,
CFP and Venus, which will serve as the FRET donor and
acceptor, respectively (Figure 1A). We expected that the acety-
lation of the substrate histone H4K12 and its subsequent binding
to the BRD2 bromodomain would induce a conformational496 Chemistry & Biology 18, 495–507, April 22, 2011 ª2011 Elsevier Ltd All rights reservedchange in the probe protein, thereby
changing the intramolecular FRET from
CFP to Venus and allowing acetylation
at H4K12 to be detected. We constructed
six potential indicators and evaluated
their ability to change the 480 nm/
535 nm emission ratio in response to tri-
chostatin A (TSA) (Yoshida et al., 1990),
a potent HDAC inhibitor, in cultured cells
(see Figures S1A and S1B available on-
line). We designated the most promising
probe, VB4HC, as Histac-K12, and chose
it for further study (Figure 1A; Figure S1A).
Histac-K12 colocalized with nuclear
DNA that was stained with Hoechst
33342 in COS7 cells (Figure 1B). To
further investigate whether Histac-K12was incorporated into chromatin, we fractionated extracts of
cells expressing Histac-K12. Immunoblot analysis of the cyto-
plasmic (Cy), nucleoplasmic (Nu), and chromatin (Ch) fractions
showed that Histac-K12 was localized in the chromatin fraction
(Figure S1C). In addition, we examined the effects of Histac-
K12 expression on chromatin structure using micrococcal
nuclease digestion, which can distinguish the nucleosomal
formation levels from the sizes of DNA corresponding to the
nucleosomal repeats. The micrococcal nuclease digestion
pattern of Histac-K12expressing COS7 cells was comparable
to that of the untransfected control cells, suggesting that
Histac-K12 is incorporated into chromatin without causing
apparent abnormalities in the nucleosome.
Next, we verified whether the acetylation kinetics in the probe
in response to TSA is similar to that in endogenous H4. The acet-
ylation of Histac-K12 in COS7 cells could be detected within 3 hr
after TSA treatment (Figure 2A). A time course showed that
endogenous histone H4K12 had similar acetylation kinetics. Fig-
ure 2BandMovie S1 show images of aCOS7cell expressingHis-
tac-K12 upon TSA treatment; the 480 nm/535 nm emission ratio
is indicated with pseudocolors. The response reached a plateau
within 3 hr after TSA treatment (Figure 2C). Immunoblot analysis
showed that the length of time required to reach the plateau was
similar to that for Histac-K12 acetylation (Figures 2A and 2C).
After removing TSA from the culture, both the emission ratio
and acetylation of Histac-K12 rapidly returned to basal levels,
indicating that Histac-K12 is a reversible indicator of histone H4
acetylation in living cells (Figure 2E; Figure S2B and Movie S2).
Photobleaching of Venus resulted in an increase in CFP fluores-
cence (Figure S2A), and the photobleached indicator no longer
Figure 2. FRET Response of Histac-K12 to Acetylation of Histone H4K12 after TSA Stimulation
(A) Histac-K12–expressing COS7 cells and untransfected COS7 cells were treatedwith 1 mMTSA. Immunoblot analyses were performed using antibodies against
GFP, histone H4, and histone H4 acetylated at Lys12.
(B andC) Pseudocolored images and a time course of the emission ratio in the nucleus of a Histac-K12–expressing COS7 cell. TSA at a final concentration of 1 mM
or the vehicle control was added to the culture at 0 min.
(D) Changes in the emission ratio (mean ± SD) in cells that were treated with 1 mM TSA for 3 hr after Venus within Histac-K12 was photobleached. Asterisk
indicates p < 0.05 compared with Histac-K12 and Histac-K12 treated with TSA, respectively.
(E) Emission ratio time courses of cells expressing Histac-K12 treated with TSA. TSA was added to the culture at 0 min and washout at 180 min.
See Figure S2 and Movies S1 and S2.
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Real-Time Imaging of Histone H4K12 Acetylationresponded to TSA (Figure 2D), indicating that the change in the
emission ratio reflects the change in FRET from CFP to Venus.
We also examined the dose response of Histac-K12 to TSA
treatment. The minimum concentration of TSA required to
induce a change in the emission ratio was approximately 1 nM
(Figures 3A and 3B). In contrast, 10 nM of TSA was required to
detect the change in acetylation by immunoblotting (FiguresChemistry & Biology 18,3C and 3D). Thus, Histac-K12 is more sensitive than immunoblot
analysis to detect histone H4K12 acetylation.
Mutational Analysis of Acetylation Sites and
Acetylation-Binding Domains
To verify that the TSA-induced change in FRET reflects the acet-
ylation of H4K12 in the probe, we tested the effects of mutating495–507, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 497
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Figure 3. Comparison of Immunoblotting Analysis with Imaging Analysis Using Histac-K12
(A and B) Time course of the emission ratio (A) and changes in the emission ratios (B) of Histac-K12–expressing cells that were treated with TSA. Data are the
means ± SD from three independent experiments. Asterisk indicates p < 0.05 compared with control.
(C and D) The immunoblot analysis was performed with antibodies against histone H4 and histone H4 acetylated at Lys12. COS7 cells were treated with various
concentrations of TSA at 37C for 3 hr. Data are the means ± SD from three independent experiments. Asterisk indicates p < 0.05 compared with control.
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Real-Time Imaging of Histone H4K12 Acetylationthe acetylation sites in histone H4 of the probe. Substituting argi-
nines for the lysine residues at all four acetylation sites (K5, K8,
K12, and K16) of histone H4 in the probe (4KR) resulted in
a loss of the response to TSA treatment (Figure 4A). Replacing
K12 with arginine also dramatically decreased the response to
an almost undetectable level. In clear contrast, any single substi-
tutions at K5, K8, or K16 or the triple substitution mutant
K5+8+16R did not significantly decrease the FRET response.
Previous studies indicated that acetylation of histone H4K12 is
one mark for newly synthesized histones (Sobel et al., 1995).
Therefore, it is possible that incomplete incorporation of newly
synthesized Histac-K12R resulted in the decreased response
to TSA. To test this possibility, we examined whether K12R
was incorporated into chromatin. Fractionation analyses
showed that Histac-K12R was normally incorporated into chro-
matin (Figure S1C). These data demonstrate that Histac-K12 is
a specific indicator that can be used to visualize the acetylation
of histone H4K12.
Next we examined the effects of mutations in the Histac-K12
BRD2 bromodomain on the FRET response in order to confirm
the role of the bromodomain. The bromodomain is generally
composed of four a helices with two loops (Zeng and Zhou,
2002). The BRD2 bromodomain consists of two domains, BD1498 Chemistry & Biology 18, 495–507, April 22, 2011 ª2011 Elsevierand BD2. Y113 and Y386 in the loops of BD1 and BD2, respec-
tively, are highly conserved throughout the large family of bromo-
domain-containing proteins, such as PCAF, GCN5, TAF1, CBP,
p300 (Zeng and Zhou, 2002), and the BET family proteins (Ume-
hara et al., 2010a; Umehara et al., 2010b). Previous studies have
shown that mutating both of these tyrosine residues in the BRD2
bromodomain was sufficient to abolish the interaction with
histone H4K12 (Kanno et al., 2004; Dhalluin et al., 1999; Owen
et al., 2000). When these two tyrosine residues were replaced
with phenylalanine (Figure 4B), the double-bromodomain mutant
(BD1+2Y/F) was incapable of binding to acetylated histone H4
(Figure4C) and failed to respond toTSA in vivo (Figure4D). Impor-
tantly, the single Y113Fmutant in BD1 (BD1Y/F) was sufficient to
impair both the ability to bind to acetylated histoneH4 (Figure 4C)
and the FRET response to TSA treatment (Figure 4D). In contrast,
the Y386F mutant in BD2 (BD2Y/F) retained the ability to bind to
acetylated histoneH4 (Figure 4C) and showed a similar change in
the emission ratio as wild-type (WT) (Figure 4D). These data
clearly indicate that BD1 plays a primary role in recognizing acet-
ylated H4K12, which was supported by the observation that
substituting alanine for Y113 (Y113A) decreases BD1 binding to
the acetylated H4K12 tail peptide, as measured by surface plas-
mon resonance (SPR) spectroscopy (Umehara et al., 2010a).Ltd All rights reserved
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Figure 4. Mutational Analysis of Acetylation Sites and Acetylation-Binding Domains
(A) Changes in the emission ratio (mean ± SD) of Histac-K12 mutants that were exposed to 1 mM TSA for 3 hr. Asterisk indicates p < 0.05 compared with
Histac-K12.
(B) The schematic representation shows the domain structure of BRD2. YF is a bromodomain mutant in which Tyr113 and 386 of BRD2 are replaced with Phe.
(C) Peptide pull-down assay using unmodified or acetylated (Ac) histone H4 N-terminal tail peptides. Pull-downs were analyzed by immunoblotting using an
anti-GFP antibody.
(D) Changes in the emission ratio of Histac-K12 mutants that were treated with 1 mM TSA for 3 hr. Data are the means ± SD from three independent experiments.
Asterisk indicates p < 0.05 compared with Histac-K12.
See Figure S3.
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Using Histac, we previously showed that acetylation of histone
H4K5/K8 was decreased during mitosis but recovered in G1
phase (Sasaki et al., 2009). To test whether H4K12 acetylation
is similarly regulated throughout the cell cycle, we monitored
the H4K12 acetylation levels using Histac-K12 and found thatChemistry & Biology 18,H4K12 acetylation was maintained during mitosis (Figures 5A
and 5B and Movie S3). Consistent with this finding, the levels
of acetylated histone H4K12 detected by immunoblotting were
retained even in M phase cells that were arrested with nocoda-
zole, unlike the drastic decreases in the levels of acetylated
histones H4K5 and K8 (Figure 5C).495–507, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 499
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Figure 5. Live Imaging of Histac-K12 During
Mitosis
(A) Pseudocolored images of the 480 nm/535 nm
emission ratio obtained from a COS7 cell ex-
pressing the acetylation indicator during mitosis.
(B) Time courses of the 480 nm/535 nm emission
ratio of Histac-K12 (B) and Histac (C).
(C) The acetylation of histone H4 at K12 asyn-
chronous (A) and nocodazole-treated (N) COS7
cells was analyzed by immunoblotting using anti-
bodies against histone H4 acetylated at K5, K8,
and K12. Phosphorylated histone H3S10 (pS10),
a mitotic marker, was analyzed by immunoblotting
using an antibody against phosphorylated histone
H3. COS7 cells were arrested inmitosis by treating
with 50 ng/ml nocodazole for 8 hr.
See Movie S3.
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Acetylation of histone H4K12 has been associated with the
general transcription of cell cycle–related genes (LeRoy et al.,
2008), genetic disorders such as the neurodegenerative disease
Friedreich’s ataxia (Herman et al., 2006), and age-dependent
memory impairment (Peleg et al., 2010). Because H4K12 acety-
lation is dynamically regulated throughout the genome, Histac-
K12 is a suitable tool to characterize the cellular response to
HDAC inhibitors. TSA is a potent pan-HDAC inhibitor that revers-
ibly blocks the activity of essentially all class I and II HDACs. On
the other hand, trapoxin B (TPX B) (Figure S4A) is another micro-
bial metabolite that inhibits class I and II HDACs, except HDAC6
(Kijima et al., 1993; Matsuyama et al., 2002). In contrast to TSA,
TPX B is a tight-binding inhibitor, likely because it covalently
binds to the catalytic pocket via its epoxyketone moiety. There-
fore, we tested the reversibility of enzyme inhibition by these500 Chemistry & Biology 18, 495–507, April 22, 2011 ª2011 Elsevier Ltd All rights reservedinhibitors using Histac-K12. In contrast
to the reversible response to TSA, the
acetylation levels increased by TPX B re-
mained high even after it was removed,
confirming that TPX B is a tight-bind
and slow off inhibitor (Figures S4B and
S4C). We next tested FK228 (Figure 6A),
which is a cyclic depsipeptide with an in-
tramolecular disulfide bond (Nakajima
et al., 1998). We previously demonstrated
that a thiol group generated from the
FK228 disulfide due to the intracellular
reducing activity is responsible for inter-
actingwith the active-site zinc in the cata-
lytic pocket of HDAC enzymes (Furumai
et al., 2002). We detected a rapid
increase in histone H4K12 acetylation
after adding FK228 (Figure 6B). However,
histone H4K12 acetylation induced by
FK228 was persistent after FK228
removal from the medium; the emission
ratio remained unchanged for 24 hr after
FK228 was removed from the culture
(Figure S4D). This long-term acetylation
of endogeneous histone H4K12 and His-tac-K12 was verified by immunoblot analysis (Figure 6C; Fig-
ure S4F). Because it is possible that the tight binding of the thiol
group to the HDAC pocket zinc was generally responsible for the
stable H4K12 acetylation, we also examined the reversibility of
histone H4K12 acetylation by Ky-6 (Nishino et al., 2003) (Fig-
ure 6A), which also contains a disulfide bond. The Ky-6 activity
was reversible, and both the emission ratio and the acetylation
level in immunoblot analyses reverted to the original levels 2 hr
after drug removal (Figures 6D and 6E). These results suggest
that a structure other than the disulfide bond in FK228 is respon-
sible for the lasting inhibition in vivo. Finally, we tested MS-275,
which is a clinically studied synthetic benzamide derivative (Fig-
ure 6A) (Saito et al., 1999). MS-275–treated cells also showed
a continuous response for at least 24 hr after compound removal
(Figure 6F; Figure S4F), which was also confirmed by immuno-
blotting (Figure 6G; Figure S4G).
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Figure 6. Dynamics Analysis of Acetylation of Histone H4K12 in Living Cells Using Various HDAC Inhibitors
(A) Structure of HDAC inhibitors FK228 (i), Ky-6 (ii), and MS-275 (iii).
(B–G) Time courses of the emission ratio (B, D, and F) and acetylation of histone H4K12 (C, E, and G) in Histac-K12-expressing cells that were treated with FK228
(B and C), Ky-6 (D and E), or MS-275 (F and G). Each HDAC inhibitor was added to the culture at 0 min and washed out at 180 min for FK228 and MS-275 or
120 min for Ky-6.
See Figure S4.
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Inhibitor Using Histac-K12
Because Histac-K12 can detect changes in the physical interac-
tion between acetylated histone H4K12 and the BRD2 bromodo-
main, it is theoretically possible to detect not only HAT or HDAC
inhibitors that change the acetylation status but also compounds
that directly interfere with the interaction between acetylated
H4K12 and the BRD2 bromodomains on the basis of changes
in the emission ratio of this probe. To validate the potentialChemistry & Biology 18,usefulness of Histac-K12 to detect such a bromodomain inhib-
itor, we used Histac-K12 to screen for an inhibitor of BD1 in
BRD2. On the basis of our crystal structures of the BRD2-BD1
bromodomain (Umehara et al., 2010a; Nakamura et al., 2007),
we searched for compounds that interact with BRD2-BD1
among commercially available compounds using a combination
of computational and biochemical analyses. The structural coor-
dinates of the residues composing the BRD2-BD1 bromodomain
(PDB ID: 1x0j) were used for computational docking screening,495–507, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 501
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Real-Time Imaging of Histone H4K12 Acetylationusing the Dock 4.0 and Autodock 3.0.5 programs, against
a nonredundant compound library of nine compound databases.
On the basis of top scores of the docking calculations, we
selected 192 compounds out of 628,402 compounds that were
filtered out according to Lipinski’s rule of five (Lipinski et al.,
2001). Then we examined the ability of each of these 192
compounds to biochemically interact with the BRD2-BD1
bromodomain by SPR and identified four candidate compounds
as potential BRD2-BD1–interactive compounds (data not
shown). These compounds were further screened using
Histac-K12–expressing COS7 cells. When the cells were treated
only with TSA, we observed a marked increase in the change of
the emission ratio, as expected (Figure 7A). Interestingly, when
the cells were treated with TSA and one of the four candidate
compounds, which was designated BIC1 (BRD2-interactive
compound-1), the increase in the emission ratio was markedly
suppressed in a dose-dependent manner (Figure 7A). These
results suggest that, although K12 of Histac-K12 was hyperace-
tylated by TSA treatment, the BRD2-BD1 domain of Histac-K12
could not bind to the H4 region, presumably because BIC1
bound to the BD1 domain of the probe and blocked its ability
to bind to acetylated H4K12. Immunoblot analysis showed that
BIC1 did not affect the acetylation level of Histac-K12 or that
of endogeneous histone H4K12 in TSA-treated cells, indicating
that BIC1 inhibited the interaction between the BRD2 bromodo-
main and acetylated histone H4K12 without affecting the K12
acetylation of histone H4 (Figure S5A). Of note, the increase in
emission ratio of Histac in response to TSA was partially
suppressed by BIC1 (Figure S5B), suggesting that BIC1 also
weakly inhibits the interaction between the BRDT bromodomain
and acetylated histone H4. The chemical structure of BIC1,
1-[2-(1H-benzimidazol-2-ylthio)ethyl]-1,3-dihydro-3-methyl-2H-
benzimidazole-2-thione, is shown in Figure 7B. We also
confirmed that BIC1 directly interacted with the BRD2-BD1
protein with a dissociation constant of 28 ± 0.2 mM, as measured
by SPR spectroscopy (Figure 7C).
Inhibition of BRD2-Dependent Transcription
by the BIC1 Compound
To date, the strongest binding between an acetylated histone tail
and a BET bromodomain is 21.9 mM, which was observed
between the K5/K8-diacetylated H4 tail and the BD1 bromodo-
main of BRDT (Morinie`re et al., 2009). The dissociation constant
of the K12-acetylated H4 tail from the BRD2-BD1 protein is
930 mM (Umehara et al., 2010a). Thus, BIC1 is assumed to inhibit
the BRD2 bromodomain in vivo. Because BRD2 enhances the
promoter activity of mammalian cells in response to active Ras
(RasV12) through the association of the bromodomains with
K12-acetylated histone H4 (Kanno et al., 2004; Denis et al.,
2000), we examined whether BIC1 represses the BRD2-depen-
dent transcriptional activation of a reporter gene in HeLa cells.
We established a luciferase assay system in which the luciferase
gene driven by the SV40 promoter was activated approximately
six-fold in the presence of RasV12 when the full-length BRD2
was introduced (Figure 7D). As expected, the addition of BIC1
at final concentrations of 5 mM or 10 mM significantly decreased
the BRD2-dependent transcriptional activation of the luciferase
gene (Figure 7D), suggesting that BIC1 is capable of blocking
the transcriptional activity of BRD2 in human cells.502 Chemistry & Biology 18, 495–507, April 22, 2011 ª2011 ElsevierCrystal Structure Analysis of the BIC1-Bound BRD2
Bromodomain
To confirm that BIC1 directly binds to the bromodomain cavity of
BRD2-BD1, we solved the crystal structure of the compound-
bound form of BRD2-BD1. After soaking the apo-form of
BRD2-BD1 crystals in a BIC1-containing solution, we obtained
an Fo - Fc electron density map showing that BIC1 bound to
the BRD2-BD1 cavity and solved the crystal structure of the
compound-bound BRD2-BD1 domain at 2.30 A˚ resolution. The
crystallographic statistics are summarized in Table S1.
As shown in Figure 7E, one benzimidazole ring of BIC1 is
located in the BRD2-BD1 cavity, and the other benzimidazole-
2-thione ring is located at the cavity periphery. In the cavity,
one of the two nitrogen atoms of the benzimidazole ring forms
hydrogen bonds with the carbonyl group of the P98 main
chain of BRD2-BD1 and with a water molecule (Figure 7E). The
direction of the aromatic benzimidazole ring seems to be hydro-
phobically stabilized by V103 and I162. At the periphery of the
BRD2-BD1 cavity, the benzimidazole-2-thione ring hydrophobi-
cally interacts with the side chains of W97 and I162, which is
different from the binding mode of the natural substrate, the
K12-acetylated histone H4 tail (Figure 7F). These structural
analyses revealed that BIC1 interacts with the bromodomain
cavity of BRD2-BD1, indicating the mechanism by which this
compound prevents BRD2 from associating with acetylated
H4K12.
DISCUSSION
Technical limitations have made it extremely difficult to spatially
and temporally analyze histone acetylation in vivo.We previously
developedHistac, the first fluorescent probe that can specifically
visualize acetylated H4K5/K8 in living cells using FRET (Sasaki
et al., 2009), in which the emission ratio is altered when a confor-
mational change is induced via the interaction between acety-
lated histone H4K5/K8 and the BRDT bromodomain. Indeed,
HDAC inhibitors such as TSA greatly increased the emission
ratio by inducing histone hyperacetylation. In this study, we
used this technology to develop a novel fluorescent probe,
Histac-K12, which allows histone H4K12 acetylation to be visu-
alized in living cells. Histac-K12 was incorporated into chromatin
and was acetylated with kinetics that were similar to those the
acetylation of endogenous histone H4K12. The emission ratio
was not increased when the probe was mutated at K12
(Histac-K12R). Therefore, the interaction between acetylated
lysine and the BRD2 bromodomain seems to occur only on the
same probe molecule, although the X-ray crystal structure
indicates that it is possible for the bromodomain to access the
acetylation site of the endogenous histone H4 molecule packed
into the same nucleosome (Sasaki et al., 2009; Harp et al., 2000;
Huston et al., 1988). Interestingly, immunoblot analysis showed
that acetylation at K5 in Histac-K12R also decreased to an
almost undetectable level (Figure S3). These results suggest
that acetylation at K5 and possibly K8 is regulated by K12 acet-
ylation, as was previously reported (Sasaki et al., 2009).
The dynamic behavior of histone H4 acetylation during mitosis
remains obscure. Using Histac, we previously showed that K5/
K8 acetylation is dramatically reduced in metaphase and
anaphase. It is possible that histone deacetylation is involvedLtd All rights reserved
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Figure 7. Identification and Evaluation of a BRD2 Bromodomain-Interactive Compound, BIC1
(A) Effects of BIC1 treatment on the Histac-K12 probe response. Cells expressing Histac-K12 were treated with 0, 10, or 60 mMBIC1 in the presence of 1 mMTSA
to stimulate histone acetylation andwere observed for 3 hr on anOlympus IX81microscope. Inhibition of the interactionwasmonitored according to the change in
the 480 nm/535 nm emission ratio (mean ± SD) of Histac-K12 every 1 hr.
(B) Chemical structure of BIC1.
(C) In vitro binding between BRD2-BD1 and BIC1. The dose-dependent binding results with compound concentrations ranging from 1.25 mM to 80 mMare shown.
The effects of the buffer were subtracted from each binding result, and the resulting score was evaluated based on the average resonance unit at 80 mM of the
compound as 100%.
(D) Inhibition of BRD2-dependent transcription by BIC1. Open and filled boxes indicate the levels of BRD2-independent and BRD2-dependent transcription,
respectively.
(E) Crystal structure of BIC1-bound BRD2-BD1. BIC1 is shown in green sticks. Nitrogen and sulfur atoms are indicated in blue and yellow, respectively. The
BRD2-BD1 bromodomain is shown in gray sticks with a semitransparent surface, and the water molecule that interacts with the BIC1 compound is shown as
a small red ball. Y113 and N156 that are involved in recognizing the Nz-acetylated H4 lysine are shown in cyan. Other BRD2-BD1 residues involved in the
compound binding are highlighted in orange (W97, V103, and I162) or magenta (P98).
(F) Acetylated H4 tail-bindingmode of BRD2-BD1. For comparison, the crystal structure of acetylated H4 tail peptide-bound BRD2-BD1 (PDB ID: 2dvq) is shown.
The acetylated histone H4 tail peptide is shown as yellow sticks. Nitrogen and oxygen atoms are indicated in blue and red, respectively. ‘‘K12ac’’ denotes the
Nz-acetylated lysine at position 12 of histone H4.
See Table S1.
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G2/M cell cycle arrest and mitotic checkpoint activation (Yosh-
ida and Beppu, 1988; Bolden et al., 2006). In contrast, recent
studies using immunofluorescent staining and immunoblotting
suggest that histone H4K12 acetylation is retained in mitosis
(Kruhlak et al., 2001; Valls et al., 2005), whereas another analysis
using mass spectrometry suggested that histone H4K12 is
deacetylated during mitosis (Bonenfant et al., 2007). Here we
demonstrated that H4K12 acetylation does not significantly
change duringmitosis in living cells. Interestingly, BRD4, another
BET family protein, localizes to chromosomes duringmitosis and
has been implicated in holding mitotic memory (Dey et al., 2003).
BRD4 may mark genes for transcriptional memory during
mitosis, and this mark acts as a signal to initiate prompt tran-
scription in daughter cells (Dey et al., 2009). BRD2 has also
been shown to localize on mitotic chromosomes and to be
involved in the transcription of cell cycle–related genes such as
cyclin D1, suggesting that BRD2 is maintained throughout
mitosis in order to ensure gene expression in the early G1 phase.
It is likely that bromodomain-mediated recognition of acetylated
H4 is crucial to retain BRD2 on mitotic chromosomes (Kanno
et al., 2004). It is also possible that BRD2 protects acetylated
H4K12 from deacetylating enzymes. However, Histac-K12 was
a sensitive sensor that dynamically monitored not only increases
but also decreases in the cellular level of H4K12 acetylation after
TSA removal, suggesting that at least the BRD2 bromodomain
itself within the probe cannot protect the acetylated residue
from HDACs.
When evaluating various HDAC inhibitors using Histac-K12,
we found that the effects of FK228 andMS-275 were long lasting
in cells, whereas that of Ky-6 was rapidly reversed after removal.
The action of MS-275, a synthetic benzamide derivative,
requires its S30-amino group to bind and inhibit class I HDACs
(Saito et al., 1999). Importantly, the recent computational simu-
lation suggests that benzamide derivatives form a stable
complex with the active site of HDAC2 (Bressi et al., 2010), which
may be responsible for the long lasting effect of MS-275 in cells.
MS-275 is currently being evaluated in clinical trials as an anti-
tumor drug (Park et al., 2004; Kazantsev and Thompson,
2008), and the clinical pharmacokinetics show that it has
a long terminal half-life of 45–100 hr (Hess-Stumpp et al.,
2007). The stable binding to HDAC in cells may explain its
long-term effects in vivo. FK228 has an intramolecular disulfide
bond and is activated in cells by reduction, which generates
two thiol groups, one of which can interact with the HDAC active
site (Furumai et al., 2002). Previous studies showed that FK228
can reversibly interact with the HDAC active site, as demon-
strated by in vitro HDAC activity assays (Furumai et al., 2002).
However, the present results are consistent with a recent study
that FK228-treated cells maintained high histone acetylation
levels even after the compound removal (Crabb et al., 2008).
Given the reversible effect of Ky-6, another thiol-containing
inhibitor, the cyclic depsipeptide structure of FK228 may be
responsible for the long-lasting effect. It seems possible that
an unsaturated amino acid in the depsipeptide ring forms a cova-
lent bond with the enzyme by a Michael-type addition. The long-
lasting effect of FK228might be due to its poor efflux fromcells. It
is also possible that, like MS-275, the FK228-enzyme complex is
stable in cells. In addition, turnover of FK228-senstive HDACs504 Chemistry & Biology 18, 495–507, April 22, 2011 ª2011 Elseviermay also affect the Histac-K12 response after drug removal.
Further study is needed for elucidating the mechanism of the
long lasting effect of FK228.
The Histac-K12 probe was useful not only to validate H4K12
acetylation and deacetylation by several HDAC inhibitors but
also to validate compounds that modulate the interaction
between acetylated H4K12 and the BRD2 bromodomain. We
identified BIC1 as a small molecule that inhibits the ability of
the BRD2 bromodomain to bind to acetylated H4K12 (Figures
7A and 7B). BRD2 has been shown to interact with the chro-
matin-binding domain of latency-associated nuclear antigen 1
(LANA-1) in Kaposi’s sarcoma–associated herpesvirus (KSHV).
LANA-1 mediates the episomal replication of the KSHV genome
and regulates transcription in latently infected cells. LANA-1
must interact with cellular chromatin for both of these functions,
and BRD2 is necessary for the interaction between LANA-1 and
chromatin (Viejo-Borbolla et al., 2005; Ottinger et al., 2006).
Therefore, BRD2 is a promising target to prevent KSVH transmis-
sion. However, there has been no rapid and convenient method
to evaluate the interaction between BRD2 and acetylated
histone H4 in living cells. Using Histac-K12, we characterized
the ability of BIC1 to inhibit BRD2 bromodomain binding to acet-
ylated histone H4 in cells by monitoring the response of Histac-
K12 to increased histone H4 acetylation in the presence of BIC1.
We also confirmed that BIC1 bound to the BRD2-BD1 bromodo-
main cavity in vitro (Figure 7E) and inhibited BRD2-dependent
transcription in cells (Figure 7D). Thus, Histac-K12 not only
provides a novel tool to spatially and temporally analyze histone
acetylation in various cellular systems, but also serves as
a powerful tool to evaluate small molecules that regulate the
writing, reading, and erasing of the histone H4K12 code.
SIGNIFICANCE
Site-specific histone acetylation plays an important role as
an epigenetic mark, which functions as cellular memory
during the cell cycle by regulating gene expression.
Recently, takingadvantageof specificbindingof abromodo-
main to acetylated lysine residues of histone H4, we suc-
ceeded in developing the first FRET-based probe for visual-
izing acetylated K5/K8 of histone H4 in living cells, named
‘‘Histac.’’ To understand the dynamics of site-specific acet-
ylation in more detail, we expanded this method to K12 of
histone H4. By utilizing the bromodomain region of BRD2,
which specifically recognizes K12-acetylated histone H4,
we developed a probe for visualizing acetylation of histone
H4K12, named Histac-K12. Using Histac-K12, we demon-
strated that H4K12 acetylation is retained during mitosis in
living cells. Histac-K12 allows quantitative evaluation
and functional discrimination of compounds that affect
H4K12 acetylation in vivo, as exemplified with three HDAC
inhibitors: FK228, MS-275, and Ky-6. In addition to HDAC
inhibitors, the Histac-K12 probe was also demonstrated to
be useful in validating a compound that modulates the inter-
action between acetylated H4K12 and BRD2 bromodomain.
Using Histac-K12, we identified an inhibitor for BRD2
bromodomain binding to acetylated H4K12 (BIC1) by moni-
toring the FRET emission ratio in the treated cells. Thus,
Histac-K12 provides a novel tool not only for spatial andLtd All rights reserved
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cellular systems but also for evaluating regulatory factors,
including small compounds that modulate acetylation of
histone H4K12. Recently, Filippakopoulos et al., (2010) iden-
tified a first inhibitor of bromodomains and demonstrated
the importance of the bromodomains as a target for an anti-
cancer drug discovery. Development of novel tools such as
Histac-K12 will be increasingly important for evaluating the
activity of epigenetic readers.
EXPERIMENTAL PROCEDURES
Cell Imaging
After transfection, the culture medium was replaced with phenol red-free
growthmedium for imaging. The cells were examined at 37C in 5%CO2 using
an Olympus IX81 microscope with a UIC-QE cooled charged-coupled device
camera (Molecular Devices). Images were collected using a MetaFluor
(Universal Imaging) with a 440AF21 excitation filter, a 455DRLP dichroic mirror,
and two emission filters (480AF30 for CFP and 535AF26 for Venus). For Fig-
ure S2A, the images of Hoechst 33342 staining and Venus were collected
with an FV1000 (Olympus) confocal microscope system.
Gel Electrophoresis and Immunoblot Analysis
For Figure 4C, the peptide pull-down assays were performed as described by
Pivot-Pajot et al. (2003). COS7 cells were transiently transfected with mono-
meric Venus-BRD2 or the monomeric Venus-BRD2 mutants. For Figure S1C,
mononucleosome core particles were purified as described by Kanda et al.
(1998). The fractions were immunoprecipitated using an anti-GFP antibody
(Takara Bio). The proteins were separated by SDS-PAGE and transferred to
a PVDF membrane (Millipore) by electroblotting. After the membranes were
incubated with the appropriate primary and secondary antibodies, the immune
complexes were detected with an Immobilon Western kit (Millipore) or ECL
Western Blotting Detection Reagents (GE Healthcare Bio-Science Corp.),
and luminescence was analyzed with a LAS3000mini image analyzer (Fujifilm).
The antibodies that recognize acetyl-lysine 5, 8, and 12 of histone H4 and
phospho-serine 10 of histone H3 were obtained from Upstate Biotechnology.
The anti-histone H3, anti-histone H4, anti-GFP, and anti-FLAG antibodies were
purchased from Cell Signaling Technology, Abcam, Takara Bio, and Sigma,
respectively. The anti-HDAC1 and anti-tubulin antibodies were obtained
from Sigma.
Surface Plasmon Resonance Analysis
To measure the dissociation constants between BRD2-BD1 and the BIC1
compound, tag-cleaved BRD2-BD1 protein was immobilized on the CM5
sensor chip (GE Healthcare) by the amine-coupling method, and SPR analysis
was performed using a Biacore 3000 (GE Healthcare). The BIC1 compound
(concentrations, 1.25–80 mM) was loaded for 60 s with a 10 ml/min flow rate
onto the chip at room temperature, and the flow was further continued for
180 s to detect the dissociation of the proteins from the immobilized peptides
in HBS-EP running buffer (10 mMHEPES [pH 7.4], 150 mMNaCl, 3 mM EDTA,
and 0.005% Tween-20). Control surfaces with no protein attached were used
to correct for the refractive index differences between the samples and the
running buffer. The results were analyzed using the BIAevaluation software
version 4.1 (GE Healthcare).
Crystal Structure Analysis
Crystallization was performed using the hanging-drop vapor-diffusion method
by mixing 1.0 ml of protein solution (5 mg/ml in 20 mM Tris-HCl buffer [pH 8.0]
containing 150 mM NaCl and 2 mM DTT) with 1.0 ml of various reservoir solu-
tions, and equilibrating the mixtures against 500 ml of the reservoir solution at
20C (Umehara et al., 2010a). Single BRD2-BD1 crystals grewwithin one week
in a drop containing 25%–30%PEGMME 5000, 0.2 M ammonium sulfate, and
0.1MHEPES buffer (pH 7.5). The crystals were soaked in the reservoir solution
containing 5 mM BIC1 for 10–20 min and were transferred in a cryoprotectant
containing 10% (w/v) glycerol. The compound-soaked crystals were flash-
cooled in liquid nitrogen prior to data collection. Diffraction data were collectedChemistry & Biology 18,under cryogenic conditions using a Rigaku FR-E Cu Ka rotating-anode X-ray
generator operated at 45 kV and 45 mA and equipped with a Rigaku RAXIS
IV2+ Imaging plate area detector and X-streamlow temperature system. The
dataset was processed and scaledwith the HKL2000 program suite (Otwinow-
ski and Minor, 1997). The compound-bound structure was solved by the
molecular replacement method, employing the apo-form of BRD2-BD1 as
a search model (Nakamura et al., 2007). The stereochemistry of the structure
is excellent, as assessed by PROCHECK (Laskowski et al., 1993). The crystal-
lographic statistics are summarized in Table S1.
ACCESSION NUMBERS
The structural coordinates of the BRD2-BD1 bromodomain complexed
with the compound BIC1 have been deposited in the Protein Data Bank under
the accession code 3aqa.
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Supplemental Information includes five figures, one table, three movies,
and Supplemental Experimental Procedures and can be found with this article
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